PART I Overview We are a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Currently, our commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline produc...
Q2 FY2026 — expected 2026-08-21
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-11 | 2025-12-31 | 0001660334-26-000008 | EDGAR | 82K words |
| 2025-03-11 | 2024-12-31 | 0000950170-25-037172 | EDGAR | — |
| 2024-02-29 | 2023-12-31 | 0000950170-24-022659 | EDGAR | — |
| 2023-03-06 | 2022-12-31 | 0000950170-23-006118 | EDGAR | — |
| 2022-03-02 | 2021-12-31 | 0000950170-22-002685 | EDGAR | — |
| 2021-03-17 | 2020-12-31 | 0001564590-21-013876 | EDGAR | — |
| 2020-03-13 | 2019-12-31 | 0001564590-20-010832 | EDGAR | — |
| 2019-03-07 | 2018-12-31 | 0001564590-19-006800 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-06 | 2026-06-30 | 0001660334-26-000025 | EDGAR | — |
| 2025-11-14 | 2025-09-30 | 0001660334-25-000006 | EDGAR | 22K words |
| 2025-08-12 | 2025-06-30 | 0000950170-25-107358 | EDGAR | — |
| 2025-05-13 | 2025-03-31 | 0000950170-25-070452 | EDGAR | — |
| 2024-11-05 | 2024-09-30 | 0000950170-24-120982 | EDGAR | — |
| 2024-08-14 | 2024-06-30 | 0000950170-24-096669 | EDGAR | — |
| 2024-05-13 | 2024-03-31 | 0000950170-24-058208 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0000950170-23-061543 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0000950170-23-039375 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0000950170-23-019169 | EDGAR | — |
| 2022-11-07 | 2022-09-30 | 0000950170-22-022647 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0000950170-22-016660 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-06 | 0001193125-26-338273 | EDGAR | — |
| 2026-03-11 | 0001193125-26-101126 | EDGAR | 6K words |
| 2025-12-30 | 0001193125-25-335824 | EDGAR | — |
| 2025-11-24 | 0001193125-25-292155 | EDGAR | — |
| 2025-11-14 | 0001193125-25-283078 | EDGAR | — |
| 2025-08-12 | 0001193125-25-178954 | EDGAR | — |
| 2025-07-30 | 0001193125-25-169309 | EDGAR | — |
| 2025-07-23 | 0001193125-25-162939 | EDGAR | — |
| 2025-07-01 | 0001193125-25-153471 | EDGAR | — |
| 2025-06-12 | 0001193125-25-139959 | EDGAR | — |
161 total filings indexed. 131 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001660334 |
| Ticker | VRCA |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.verrica.com |
| Listed | 2018-06-15 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/VRCA (~200 tokens, structured JSON with cryptographic provenance)